Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
4(44%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
4
44%
Ph phase_2
3
33%
Ph phase_1
2
22%

Phase Distribution

2

Early Stage

3

Mid Stage

4

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
2(22.2%)
Phase 2Efficacy & side effects
3(33.3%)
Phase 3Large-scale testing
4(44.4%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

9

all time

Status Distribution
Active(8)
Completed(1)

Detailed Status

Not yet recruiting4
Recruiting3
Completed1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
4
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (22.2%)
Phase 23 (33.3%)
Phase 34 (44.4%)

Trials by Status

recruiting333%
completed111%
active_not_recruiting111%
not_yet_recruiting444%

Recent Activity

4 active trials
Showing 5 of 9
not_yet_recruitingphase_2

A Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast Cancer

NCT07545044
not_yet_recruitingphase_3

JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan

NCT07384377
active_not_recruitingphase_1

Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors

NCT05744427
recruitingphase_3

JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

NCT06079983
completedphase_1

First-In-Human Study in Subjects With Advanced or Metastatic Solid Malignant Tumors

NCT05494918
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT07545044Phase 2

A Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast Cancer

Not Yet Recruiting
NCT07384377Phase 3

JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan

Not Yet Recruiting
NCT05744427Phase 1

Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors

Active Not Recruiting
NCT06079983Phase 3

JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

Recruiting
NCT05494918Phase 1

First-In-Human Study in Subjects With Advanced or Metastatic Solid Malignant Tumors

Completed
NCT05582499Phase 2

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

Recruiting
NCT06998771Phase 2

JSKN003 Combined Treatment of HER2-positive Gastric Cancer

Not Yet Recruiting
NCT06846437Phase 3

JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer

Recruiting
NCT06751485Phase 3

JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer

Not Yet Recruiting

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9